Avidity Biosciences 2025 Annual Meeting: All director nominees elected, Deloitte ratified, say-on-pay approved

Avidity Biosciences, Inc.

Class II directors elected: Levin 107.2M for (3.9M withheld), Skerjanec 110.5M for (0.8M withheld), Thompson 80.6M for (30.7M withheld, 27.6% against).
Deloitte ratified as independent auditor for FY2025: 116.7M for, 31.5K against, 51.8K abstain.
Advisory vote on named executive officer compensation passed: 80.6M for, 25.3M against, 5.3M abstain (broker non-votes 5.5M).

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.